Categories
Tags
Authors: Atoui A, Jarrah K, Al Mahmassani L, Bou-Fakhredin R, Taher AT PMID: 35083524 PMCID: PMC8791702 doi: 10.1007/s00277-021-04743-1 Abstract Severe side effects of adenoviral-vectored-DNA COVID-19 vaccines such as thrombosis have been reported. Herein, we report a case of sudden massive deep vein thrombosis (DVT) in a young man with inferior vena cava anomaly 20 hours [...]
Categories: I-RECOVER Post-Vaccine
Authors: Chen JJ, Zeng BY, Lui CC, Chen TY, Chen YW, Tseng PT PMID: 35583323 PMCID: PMC9129164 DOI: 10.1093/qjmed/hcac124 Abstract The COVID-19 vaccine had been recognized as one of the most important weapons to fight COVID-19. However, the COVID-19 vaccine-associated tinnitus, although not a severe adverse event, had attracted the clinicians’ attention gradually.1 Although it [...]
Categories: I-RECOVER Post-Vaccine
Authors: Perez JC, Moret-Chalmin C, Montagnier L DOI: 10.5281/zenodo.6641999 Abstract "Resubmitted preprint withdrawn after 132 000 reads on RESEARCHGATE" We highlight the presence of a Prion region in the different Spike proteins of the original SARS-CoV2 virus as well as of all its successive variants but also of all the “vaccines” built on this same [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19 Vaccines
Authors: Roltgen K, Nielsen SC, Silva O, Younes SF, Yang F, Wirz OF PMID: 35148837 PMCID: PMC8786601 DOI: 10.1016/j.cell.2022.01.018 Abstract During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19 Vaccines, SARS-CoV-2
Authors: Ioannou GN, Locke E, Green PK, Berry K DOI: https://doi.org/10.1016/j.eclinm.2022.101326 Abstract Background mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) have been shown to be efficacious but have not been compared in head-to-head clinical trials. Methods We designed this observational study to emulate a target trial of COVID-19 vaccination by BNT162b2 versus [...]
Categories: I-RECOVER Post-Vaccine
Authors: Kuyandik A, Ozcan E, Serin S, Sungurtekin H DOI: 10.4274/tybd.galenos.2021.91885 Abstract ABSTRACT Reports of neurological problems are increasing for the clinical presentation of COVID19. The clinical presentation reported in this study seemed to be a combination of nonspecific complications of the systemic disease, inflammation of the cerebrovascular system, and the effects of a direct [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19 Vaccines
Authors: Neil M, Fenton N, Smalley J, Craig C, Guetzkow J, Rose J DOI:10.13140/RG.2.2.14176.20483 Abstract The risk/benefit of Covid vaccines is arguably most accurately measured by an all-cause mortality rate comparison of vaccinated against unvaccinated, since it not only avoids most confounders relating to case definition but also fulfils the WHO/CDC definition of "vaccine effectiveness" [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19 Vaccines
Authors: Classen JB Abstract Many have argued that the outbreak of COVID-19 is the result of the release of a viral based bioweapon. Vaccines to COVID-19 have been developed and a policy of universal immunization has been initiated with total disregard to the fact that the virus may be a bioweapon. The potential risk [...]
Categories: I-RECOVER Post-Vaccine